Related Experiment Video
Updated: Aug 3, 2026
11:54
Microsatellite DNA Genotyping and Flow Cytometry Ploidy Analyses of Formalin-fixed Paraffin-embedded Hydatidiform Molar Tissues
Published on: October 20, 2019
ABO genotyping of complete hydatidiform moles
R A Fisher1, P H Johnson, S Povey
1Department of Medical Oncology, Charing Cross and Westminster Medical School, Hammersmith, London, UK.
Disease Markers
|November 1, 1993
Summary
This study determined the ABO blood group of complete hydatidiform moles (CHM) using molecular genotyping. The CHM blood group did not significantly affect the need for chemotherapy in patients.
Area of Science:
- Reproductive Medicine
- Genetics
- Oncology
Background:
- Complete hydatidiform mole (CHM) is a pregnancy complication.
- The influence of patient and CHM ABO blood groups on CHM outcomes is debated.
- CHM lack red blood cells, hindering traditional blood typing.
Purpose of the Study:
- To determine the ABO genotype of CHM using molecular methods.
- To investigate the relationship between CHM ABO genotype and patient ABO type.
- To assess if ABO blood group compatibility influences the need for chemotherapy in CHM patients.
Main Methods:
- Molecular genotyping was employed to determine the ABO genotype of 48 CHM samples.
- Patient ABO blood groups were compared with the determined CHM ABO genotypes.
- The requirement for chemotherapy was analyzed based on ABO blood group matching between patient and CHM.
Main Results:
- Molecular genotyping successfully determined the ABO genotype of all CHM.
- All CHM genotypes were consistent with their androgenetic origin.
- No significant difference in chemotherapy requirement was observed between patients with like or unlike ABO blood groups compared to their CHM.
Conclusions:
- Molecular genotyping is a feasible method for determining CHM ABO genotype.
- The ABO blood group of the CHM, irrespective of the patient's blood group, does not appear to influence the need for chemotherapy in CHM cases.
